In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS

 

Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease

Session Clinical Case Poster session III

Speaker Luis Eduardo Juarez-Orozco

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Cross-Modality and Multi-Modality Imaging Topics
  • Session type : Clinical Case Posters
  • FP Number : 351

Authors : L E Juarez-Orozco (Turku,FI), A Saraste (Turku,FI), D Capodanno (Catania,IT), E Prescott (Copenhagen,DK), H Ballo (Turku,FI), JJ Bax (Leiden,NL), W Wijns (Galway,IE), J Knuuti (Turku,FI)

Authors:
L E Juarez-Orozco1 , A Saraste2 , D Capodanno3 , E Prescott4 , H Ballo2 , JJ Bax5 , W Wijns6 , J Knuuti2 , 1Turku PET Centre - Turku - Finland , 2Turku University Hospital, PET Center - Turku - Finland , 3University Hospital Vittorio Emanuele, Cardiac-Thoracic-Vascular Department - Catania - Italy , 4Bispebjerg University Hospital, Cardiology - Copenhagen - Denmark , 5Leiden University Medical Center, Cardiology - Leiden - Netherlands (The) , 6Saolta University Healthcare Group, National University of Ireland Galway, 5) The Lambe Institute for Translational Medicine and Curam - Galway - Ireland ,

Citation:

Background.

The optimal use of cardiovascular diagnostics depends on the assumed pre-test probability (PTP) of significant coronary artery disease (CAD) and the diagnostic performance profile of the considered technique. There is indication that the prevalence of CAD in symptomatic patients has changed over the last decades and a contemporary overview of PTPs is lacking. Therefore, we sought provide a pooled estimation of contemporary PTPs of significant CAD across clinical patient categories, evaluate the utility of application of diagnostic techniques according to such estimates, and propose An optimized comprehensive diagnostic technique selection tool for suspected CAD.

Methods. Estimates of significant CAD prevalence across sex, age and type of chest complaints categories from three large-scale studies were pooled (n=15,815). These updated PTPs and diagnostic performance profiles of exercise ECG, ICA, CCTA, PET, stress CMR, and SPECT were integrated to define the PTP ranges in which ruling-out CAD (using FFR as reference standard) is possible with a post-test probability of <10% and <5%. These were integrated in a color-coded tabular diagnostic technique selection tool.

Results.

Pooled CAD prevalence was 14.9% (range=1-52), clearly lower than that used in current clinical guidelines. Ruling-out capabilities of noninvasive imaging were good overall. The greatest ruling-out capacity (i.e. post-test-probability <5%) was documented by CCTA, PET and stress CMR (PTP thresholds for a post-test probability <10 and <5%: PTP <45 and <28%, respectively). The comprehensive tool is show in the Figure.

Conclusion.

The contemporary PTP of significant CAD across symptomatic patient categories is substantially lower than currently assumed. With a low prevalence of the disease, diagnostic testing can rarely rule-in CAD and the focus should shift to ruling-out functionally obstructive CAD. A comprehensive tool may aid in technique selection when significant CAD is suspected in symptomatic patients.

This content is currently on FREE ACCESS

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are